Kovitz Investment Group Partners, LLC, an investment management company, released its “Kovitz Core Equity Strategy” ...

Becton Dickinson and Co. (BDX) on Thursday reported fiscal third-quarter earnings of $574 million. On a per-share basis, the ...

Becton, Dickinson (BDX) stock gains as the company boosts fiscal 2025 earnings outlook after better than expected Q3 results.

Becton Dickinson & Co. closed 29.80% below its 52-week high of $251.99, which the company reached on February 3rd.

The stock's rise snapped a five-day losing streak.

Hello, and welcome to BD’s Third Fiscal Quarter 2025 Earnings Call. At the request of BD, today’s call is being recorded and ...

Becton Dickinson beat Q3 earnings and revenue estimates, raised its FY25 EPS outlook, and saw strong growth in its medical ...

Although it sounds like an oxymoron, high-growth prospect dividend aristocrat stocks exist, although their industries may ...

Becton Dickinson raised its forecast for annual profit on Thursday, after beating Wall Street estimates for third-quarter profit and sales on strong demand for its drug-delivery devices.

Discover how Becton Dickinson (BDX) achieved 8.5% revenue growth, expanded margins, and raised guidance in Q3 2025.

Becton, Dickinson and Company (NYSE:BDX) is one of the top stocks that Grok recommended. On July 31, Becton, Dickinson and Company (NYSE:BDX) announced that it submitted an application to the U.S.

Waters said it reached a deal to buy the Biosciences & Diagnostic Solutions business of Becton Dickinson for around $17.5 ...